Depression in adults: recognition and management : guidance (CG90)

National Institute for Health and Care Excellence - NICE
Publication date:
28 October 2009


This guideline covers identifying and managing depression in adults aged 18 years and older, in primary and secondary care. It aims to improve care for people with depression by promoting improved recognition and treatment.

 MHRA advice on valproate: We have amended a recommendation in the section on combining and augmenting medications in line with the MHRA guidance on valproate use by women and girls. Valproate must not be used in women and girls of childbearing potential (including young girls who are likely to need treatment into their childbearing years), unless other options are unsuitable and the pregnancy prevention programme is in place. The MHRA has published temporary advice on the valproate pregnancy prevention programme during the COVID-19 pandemic

NICE has also produced a guideline on depression in adults with a chronic physical health problem.


This guideline includes recommendations on:

Who is it for?

  • Healthcare professionals
  • People with depression, their families and carers

Is this guideline up to date?

We reviewed the evidence in December 2013 and we are updating this guideline. See the guideline in development page for progress on the update.

Guideline development process

How we develop NICE guidelines 

This guideline updates and replaces NICE guideline CG23 (December 2004).